ES2158099T3 - Derivados de imidazo(1,2-a)indeno(1,2-e)pirazina-4-ona y composiciones farmaceuticas que los contienen. - Google Patents

Derivados de imidazo(1,2-a)indeno(1,2-e)pirazina-4-ona y composiciones farmaceuticas que los contienen.

Info

Publication number
ES2158099T3
ES2158099T3 ES95914404T ES95914404T ES2158099T3 ES 2158099 T3 ES2158099 T3 ES 2158099T3 ES 95914404 T ES95914404 T ES 95914404T ES 95914404 T ES95914404 T ES 95914404T ES 2158099 T3 ES2158099 T3 ES 2158099T3
Authority
ES
Spain
Prior art keywords
pct
formula
compounds
receptor
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95914404T
Other languages
English (en)
Inventor
Jean-Claude Aloup
Francois Audiau
Michel Barreau
Dominique Damour
Arielle Genevois-Borella
Patrick Jimonet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Application granted granted Critical
Publication of ES2158099T3 publication Critical patent/ES2158099T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Anesthesiology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPOSICIONES FARMACEUTICAS QUE CONTIENEN COMO PRINCIPIO ACTIVO COMPUESTOS DE FORMULA: (I) EN LA QUE R, R{SUB,1} Y R{SUB,2} SON TALES COMO SE DEFINEN EN LA DESCRIPCION O SUS SALES, LOS NUEVOS COMPUESTOS DE FORMULA (I) Y SU PREPARACION. LOS COMPUESTOS DE FORMULA (I) PRESENTAN PROPIEDADES FARMACOLOGICAS INTERESANTES. ESTOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DEL ACIDO {AL}AMINO-3-HIDROXI-5-METIL-4-ISOXAZOLEPROPIONICO (AMPA), TAMBIEN CONOCIDO BAO EL NOMBRE DE RECEPTOR DE QUISCALATO. POR OTRA PARTE, LOS COMPUESTOS DE FORMULA (I) SON ANTAGONISTAS NO COMPETITIVOS DEL RECEPTOR N-METIL-D-ASPARTATO (NMDA), Y MAS EN PARTICULAR, SON LIGANDOS PARA LOS SITIOS MODULADORES DE LA GLICINA DEL RECEPTOR NMDA.
ES95914404T 1994-03-28 1995-03-23 Derivados de imidazo(1,2-a)indeno(1,2-e)pirazina-4-ona y composiciones farmaceuticas que los contienen. Expired - Lifetime ES2158099T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9403582A FR2717813B1 (fr) 1994-03-28 1994-03-28 Dérivés d'imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one, leur préparation et les médicaments les contenant .

Publications (1)

Publication Number Publication Date
ES2158099T3 true ES2158099T3 (es) 2001-09-01

Family

ID=9461467

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95914404T Expired - Lifetime ES2158099T3 (es) 1994-03-28 1995-03-23 Derivados de imidazo(1,2-a)indeno(1,2-e)pirazina-4-ona y composiciones farmaceuticas que los contienen.

Country Status (14)

Country Link
US (1) US5807859A (es)
EP (1) EP0752992B1 (es)
JP (1) JPH09510727A (es)
AT (1) ATE201686T1 (es)
AU (1) AU2141395A (es)
DE (1) DE69521125T2 (es)
DK (1) DK0752992T3 (es)
ES (1) ES2158099T3 (es)
FR (1) FR2717813B1 (es)
GR (1) GR3035956T3 (es)
IL (1) IL113148A0 (es)
PT (1) PT752992E (es)
WO (1) WO1995026350A1 (es)
ZA (1) ZA952529B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2743364A1 (fr) * 1996-01-10 1997-07-11 Rhone Poulenc Rorer Sa Derives de 5h,10h-imidazo(1,2-a)indeno(1,2-e)pyrazine-4-one, leur preparation et les medicaments les contenant
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
JP5543209B2 (ja) * 2006-10-30 2014-07-09 ヒブリジェニクス・エスアー 新規のシステインプロテアーゼのテトラサイクリン阻害剤、その薬剤組成物および治療のためのその使用
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
DK2091948T3 (da) 2006-11-30 2012-07-23 Probiodrug Ag Nye inhibitorer af glutaminylcyclase
CA2679446C (en) 2007-03-01 2016-05-17 Probiodrug Ag New use of glutaminyl cyclase inhibitors
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
MX2012002993A (es) 2009-09-11 2012-04-19 Probiodrug Ag Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507300A (en) * 1980-05-09 1985-03-26 Usv Pharmaceutical Corporation Pyridotriazolopyrazine-diones for treating allergy
US4668678A (en) * 1980-05-09 1987-05-26 Usv Pharmaceutical Corporation Triazoloquinoxalin-1,4-diones
US4400382A (en) * 1980-05-09 1983-08-23 Usv Pharmaceutical Corporation Thiazoloquinoxalin-1,4-diones for treating allergy
US4354027A (en) * 1980-05-19 1982-10-12 Usv Pharmaceutical Corporation Triazoloquinoxalin-4-ones
US5196421A (en) * 1991-06-05 1993-03-23 Eli Lilly And Company Excitatory amino acid receptor antagonists in methods for the use thereof
US5153196A (en) * 1991-06-05 1992-10-06 Eli Lilly And Company Excitatory amino acid receptor antagonists and methods for the use thereof
DK162491D0 (da) * 1991-09-20 1991-09-20 Novo Nordisk As Heterocycliske forbindelser, deres fremstilling og farmaceutiske praeparater indeholdende forbindelserne
DE69334237D1 (de) * 1992-06-22 2008-09-25 State Of Oregon Through Oregon Glycinrezeptorantagonisten und ihre verwendung
FR2696466B1 (fr) * 1992-10-02 1994-11-25 Rhone Poulenc Rorer Sa Dérivés de 5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one, leur préparation et les médicaments les contenant.
DK12293D0 (da) * 1993-02-02 1993-02-02 Novo Nordisk As Heterocykliske forbindelser og deres fremstilling og anvendelse
FR2707645B1 (fr) * 1993-07-16 1995-08-11 Rhone Poulenc Rorer Sa Dérivés d'imidazo[1,2-a]pirazine-4-one, leur préparation et les médicaments les contenant.
FR2707643B1 (fr) * 1993-07-16 1995-08-11 Rhone Poulenc Rorer Sa Dérivés d'imidazo[1,2-a]pyrazine-4-one, leur préparation et les médicaments les contenant.

Also Published As

Publication number Publication date
EP0752992A1 (fr) 1997-01-15
IL113148A0 (en) 1995-06-29
DE69521125D1 (de) 2001-07-05
DE69521125T2 (de) 2001-11-15
EP0752992B1 (fr) 2001-05-30
ATE201686T1 (de) 2001-06-15
GR3035956T3 (en) 2001-08-31
DK0752992T3 (da) 2001-07-30
PT752992E (pt) 2001-10-31
AU2141395A (en) 1995-10-17
FR2717813A1 (fr) 1995-09-29
JPH09510727A (ja) 1997-10-28
FR2717813B1 (fr) 1996-05-10
US5807859A (en) 1998-09-15
ZA952529B (en) 1996-01-22
WO1995026350A1 (fr) 1995-10-05

Similar Documents

Publication Publication Date Title
ES2134460T3 (es) Derivados de 5h-indeno(1,2-b)-pirazina-2,3-diona, su preparacion y los medicamentos que les contienen.
ES2158099T3 (es) Derivados de imidazo(1,2-a)indeno(1,2-e)pirazina-4-ona y composiciones farmaceuticas que los contienen.
AR002268A1 (es) Antagonistas de vasopresina de benzacepina triciclicos, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso dedichos compuestos para preparar composiciones farmaceuticas.
ES2134459T3 (es) Indeno(1,2-e)pirazina-4-onas, su preparacion y los medicamentos que les contienen.
ATE177747T1 (de) Spiro(heterozyclische-imidazo(1,2-a>indeno(1,2- e>pyrazin>-4'-one, ihre herstellung und diese enthaltende arzneimittel
DE69508667T2 (de) Benzothiadiazinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
IL113365A (en) 5-Heterocyclo-1,5-benzodiazepine derivatives their preparation and pharmaceutical compositions containing them
NO301760B1 (no) Farmakologisk aktive <alfa>-[tertiær-aminometyl]-benzenmetanolderivater, farmasöytiske preparater inneholdende disse samt anvendelse av forbindelsene for fremstilling av farmasöytiske preparater

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 752992

Country of ref document: ES